| Autor: |
Harrison, Sarah K., Garrett, John S., Kohman, Kelsey N., Kline, Jeffrey A. |
| Zdroj: |
Baylor University Medical Center Proceedings; Apr-Jun2018, Vol. 31 Issue 2, p153-156, 4p |
| Abstrakt: |
The relative clinical efficacy of 4-factor prothrombin complex concentrate (4F-PCC) in oral anticoagulant--associated intracranial hemorrhage is unknown, especially for factor Xa--inhibiting anticoagulants. We report short-term outcomes of patients with oral anticoagulant--associated intracranial hemorrhage on vitamin K antagonists and factor Xa inhibitors who were treated with 4F-PCC. This multicenter, observational study involved patients presenting to the emergency department in nine hospitals in an integrated health care delivery system in Texas between July 2013 and December 2015. Forty-two patients diagnosed with oral anticoagulant--associated intracranial hemorrhage--24 taking a vitamin K antagonist and 14 taking a factor Xa inhibitor--were treated with 4F-PCC as part of usual care. Study patients had similar baseline demographics, with the exception of suspected etiology of hemorrhage. Outcomes of the vitamin K antagonist group were similar to those of the factor Xa inhibitor group, with no significant differences in overall in-hospital mortality (32.1% vs 14.2%, respectively), length of stay, or rates of hemorrhagic expansion, thromboembolism, or discharge to home. In conclusion, this small sample of patients with oral factor Xa inhibitor and vitamin K antagonist--associated intracranial hemorrhage treated with 4F-PCC had similar mortality and neurological outcomes, with no venous thromboembolic events. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
